Yazar "Fujihara, K." için listeleme
-
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
Pittock, S. J.; Berthele, A.; Fujihara, K.; Kim, H. J.; Levy, M.; Palace, J.; Wingerchuk, D. M. (Massachusetts Medical Soc, 2019)Neuromyelitis optica spectrum disorder is a relapsing inflammatory disorder of the central nervous system. Two thirds of patients have antibodies against aquaporin-4, and CNS damage is complement dependent. The inhibitor ... -
Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study
Kim, H. J.; Pittock, S. J.; Berthele, A.; Fujihara, K.; Levy, M.; Palace, J.; Wingerchuk, D. M. (Sage Publications Ltd, 2019)… -
Impact of Eculizumab on Quality of Life in AQP4+NMOSD: Findings From the PREVENT Study
Berthele, A.; Pittock, S.; Fujihara, K.; Kim, H.; Levy, M.; Palace, J.; Wingerchuk, D. (Sage Publications Ltd, 2020)… -
Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder
Wingerchuk, D. M.; Pittock, S. J.; Berthele, A.; Fujihara, K.; Kim, H. J.; Levy, M.; Armstrong, R. (Sage Publications Ltd, 2019)… -
Long-term Safety and Effectiveness of Eculizumab in Neuromyelitis Optica Spectrum Disorder
Wingerchuk, D.; Pittock, S.; Berthele, A.; Fujihara, K.; Kim, H.; Levy, M.; Armstrong, R. (Sage Publications Ltd, 2020)…
